HPA
NVAX icon

Hilltop Park Associates’s Novavax NVAX Stock Holding History

Hilltop Park Associates’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-5,000
Closed -$417K – 24
2014
Q3 		$417K Sell
5,000
-5,000
-50% -$452K 1.36% 18
2014
Q2 		$924K Buy
+10,000
New +$879K 0.88% 38

Other funds holding NVAX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Hilltop Park Associates's NVAX Position: Q4 2014 in Review

Hilltop Park Associates sold out of Novavax (NVAX) in Q4 2014, closing a stake of 5,000 shares — an estimated $417K sold.

Hilltop Park Associates first reported a position in NVAX in Q2 2014 and held it in 2 quarters. The position peaked at $924K in Q2 2014. 153 funds tracked by Wall St. Rank hold NVAX as of Q4 2014.

  • Hilltop Park Associates reported no remaining Novavax position as of Q4 2014 after selling out during the quarter.
  • Hilltop Park Associates sold 5,000 Novavax shares in Q4 2014, an estimated $417K.
  • Hilltop Park Associates first reported a position in Novavax in Q2 2014 and held it in 2 quarters.
  • Hilltop Park Associates's Novavax position peaked at $924K in Q2 2014.
  • 153 funds tracked by Wall St. Rank held Novavax as of Q4 2014.

Based on Hilltop Park Associates's 13F filing for Q4 2014, filed 17 Feb 2015.